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Purpose: The purpose of this study was to compare outcomes of subjects with open-angle
glaucoma (OAG) not controlled on one medication who underwent either implantation of two
iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed
combination of latanoprost/timolol.
Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were
randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98
to receive medical therapy.
Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedicated intraocular pressure (IOP) reduction of $20% versus baseline unmedicated IOP, and
91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction $20% versus
baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent
inject group was statistically significant (P=0.02) at the $50% level of IOP reduction. An
IOP #18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8%
of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from
screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medical therapy groups, respectively. A high safety profile was also noted in this study in both the
iStent inject and medical therapy groups, as measured by stable best corrected visual acuity,
cup-to-disc ratio, and adverse events.
Conclusion: These data show that the use of iStent inject is at least as effective as two medications, with the clinical benefit of reducing medication burden and assuring continuous treatment
with full compliance to implant therapy as well as having a highly favorable safety profile.
Keywords: ab interno, intraocular pressure, trabecular bypass, OAG, IOP reduction

Introduction

Correspondence: Antonia M Fea
Department of Clinical Physiopathology,
Eye Clinic, University of Torino,
Torino, Italy
Email antoniofea@interfree.it

Glaucoma, a debilitating and prevalent disease, is a leading cause of blindness
worldwide. The management of glaucoma requires chronic, life-long treatment with
a spectrum of therapeutic options, including medications, laser treatment, and surgical implants, with the common goal among these therapies of reducing intraocular
pressure (IOP) to a targeted level, preventing loss of visual field due to excessive
pressure on the optic nerve, and minimizing the impact on quality of life. Limitations
of currently available medical treatments can result in adverse events1 coupled with
a lack of patient compliance. These factors have prompted the development of new
therapies to preserve visual function by delivering a significant and continued decrease
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of IOP without compromising patient safety. Use of stents
to create a direct route from the anterior chamber to the
Schlemm’s canal, thus bypassing the damaged trabecular
meshwork, was researched by Spiegel et al.2 Further evolution to this technique was employed in the research and
development of micro-invasive glaucoma surgery (MIGS)
using ab interno trabecular micro-bypass stents in mildto-moderate subjects with open-angle glaucoma (OAG).
This procedure and use of the first-generation device, the
Glaukos iStent® Trabecular Micro-Bypass Stent (Glaukos
Corporation, Laguna Hills, CA, USA) was demonstrated to
be safe and effective in a prospective, randomized, multicenter US investigational device exemption clinical trial and
summarized by Samuelson et al.3 Further validation of the
device in longer term (up to 5 years) prospective, randomized
trials described by Fea et al, Craven et al, and others have
continued to demonstrate the benefits of a single iStent for
the reduction of IOP and medication burden.4–8
Implantation of two stents per glaucomatous eye has been
evaluated both in vitro and in clinical studies to investigate
whether a further increase of outflow can be accomplished.
Bahler et al demonstrated in vitro that increased outflow
above and beyond that achieved with one stent is a viable
option.9 A clinical study by Belovay et al indicated that
multiple stents during cataract surgery resulted in a mean
reduction in IOP of ,15 mmHg coupled with reduced medications through 1 year after implantation.10
To further enable implantation of multiple stents into
Schlemm’s canal, a second-generation, smaller, and coneshaped design (iStent inject® Trabecular Micro-Bypass;
Glaukos Corporation) and a modified injector preloaded
with two iStent inject devices were developed. This system
is now under study in a US pivotal trial. The study by Bahler
et al of this newer generation device using a similar method
as the previous perfusion-model study showed that the addition of a second stent further increased outflow facility to
0.78±0.66 µL/minute/mmHg.11 Long-term in vivo studies
are underway to determine long-term efficacy.
Combination glaucoma drugs enable the possibility
of synergistic medical therapies for greater IOP-lowering
effect.12–15 Although these drugs may offer IOP reduction
with increased compliance over instillation of multiple types
of medications, there are still disadvantages, including high
cost, inconvenience, potential side effects such as corneal
epithelial cell damage, and noncompliance. Taking into
consideration the current interest in combination therapies
and the usage of multiple stents for IOP-lowering effect, the
clinical trial described in this report was proposed. This final
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report summarizes the safety and efficacy clinical results at
1 year following treatment of 192 subjects randomized to
receive either two iStent inject devices or two medications.

Materials and methods
Study design
This trial, also known as the Second Line Study, was conducted at eight investigational sites in six countries (Italy,
Spain, Poland, Germany, United Kingdom, and Armenia).
The study design was a prospective, randomized trial to
compare outcomes of subjects with OAG not controlled on
one medication who underwent either implantation of two
iStent inject devices or received medical therapy consisting
of a fixed combination of latanoprost/timolol (Xalacom®;
Pfizer, New York, NY, USA). One-hundred and ninety-two
subjects were enrolled and followed for 1 year after treatment.
Subjects using one ocular hypotensive medication, who,
in the opinion of the investigator, required additional IOP
lowering to control their OAG, were screened for the trial
and were washed out of their current glaucoma medication
in the study eye prior to randomization. This included a
4-week washout for prostaglandin analogs and beta-blockers,
or 2-week washout for alpha-adrenergic agonists and carbonic anhydrase inhibitors. Final enrollment criteria were
assessed at the baseline visit. In order to qualify, subjects
presented with a post-washout IOP between $22 mmHg
and ,38 mmHg. Subjects were then randomized to receive
either implantation of two GTS400 stents in the study eye
or medical therapy (latanoprost/timolol). Other inclusion
criteria included minimum best corrected visual acuity
(BCVA) of 20/200 or better, scleral spur clearly visible by
gonioscopy, able and willing to attend follow-up visits for
1 year postoperatively, and informed consent.
Subjects were excluded if they were known nonresponders
to latanoprost, had secondary glaucoma (with the exception
of pseudoexfoliative and pigmentary), prior incisional glaucoma surgery or procedure such as trabeculectomy shunt or
collagen implant, cloudy cornea inhibiting gonioscopic view,
signs of traumatic or uveitic, neovascular, or angle-closure
glaucoma. Prior selective laser trabeculoplasty in the study
eye was allowed as long as the procedure was not performed
within 90 days prior to the screening visit.
Following the implantation of two stents or initiation of
fixed medical therapy, depending on the group assignment,
subjects followed an identical schedule of postoperative
examinations. Evaluations occurred at day 1, month 1, 3, 6,
9, and 12. IOP was measured between 8–11 am to control
for diurnal variation in IOP.
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Stent and surgical technique
Subjects randomized to surgery received two iStent inject
devices. Each iStent inject model GTS400 is a single-piece
heparin-coated, gamma-sterilized titanium stent (Figure 1).
An area of reduced outside diameter midway along the
device is designed to provide retention within the trabecular
meshwork, while multiple outlet lateral lumens (four outflow
orifices) are designed to provide an exit route for aqueous
humor from the anterior chamber. The stent is symmetrically
designed such that it may be used in either the left or right
eye. Two GTS400 stents are preloaded in the G2-M-IS injector system (Figure 2). The injector is designed to deliver the
stents automatically into Schlemm’s canal when activated
by the surgeon. The portion of the injector that enters the
eye is a 23-gauge stainless steel tube. The injector features
a surgeon-activated release button on the housing, which is
pressed to allow the stents to move over a small guiding trocar
to exit the injector. Two iStent inject devices were implanted
through the trabecular meshwork into Schlemm’s canal at
the nasal position, separated by 2–3 clock hours. Following
implantation of two iStent inject devices, subjects received
topical postoperative anti-inflammatory and anti-infective
medications for 4 weeks.
The study was initiated using the first generation G2-0
injector, which allows for insertion of one stent at a time.
Subsequently, the second-generation injector G2-M-IS
system, which is able to hold two stents, was introduced to
the study, thus providing the clinician the ability to insert
multiple stents while entering the eye only once.

Study outcomes and statistical analysis
Eff icacy measures included percentage of subjects
who achieved an IOP reduction $20% versus baseline
unmedicated IOP, percentage of subjects who achieved an
IOP #18 mmHg, mean IOP at each study visit, and mean

Insertion sleeve
retraction button

Left housing

Trigger button

Right housing

Insertion sleeve

Insertion tube
Trocar
Figure 2 G2-M-IS injector.

reduction in IOP. Safety measures assessed cup-to-disc (CD)
ratio, BCVA, and incidence of adverse events.
For the proportional analyses such as IOP reduction $20%
and IOP #18 mmHg, exact 95% confidence intervals based
on a binomial distribution were calculated for the responder
rates. For the iStent inject eyes, responders included eyes on
no medication at Month 12. For both groups, a nonresponder
assumption was used for missing data. Fisher’s exact test was
used to compare the responder rates between the two study
groups. For continuous variables such as mean IOP and IOP
reduction, mean and standard deviation (SD) were provided.
Statistical tests were performed using SAS® software version
9.1.3 (SAS Institute Inc., Cary, NC, USA).

Results
Demographics, preoperative
characteristics, and medical therapy
Subject accountability is shown in Table 1. Of the
229 subjects who were screened for the trial, 192 qualified
and were enrolled. As shown in Table 2, of the 192 subjects,
94 underwent surgery with implantation of two iStent inject
devices in the treated eye and 98 were randomized to receive
medical therapy.
Demographics and subject characteristics were similar for
both study arms (Table 2). Mean age for the iStent inject group

Inlet orifice

Table 1 Subject accountability
Outflow
orifices
(4 total)

Flange Thorax
Head
(resides in anterior chamber) (resides in (resides in Schlemm’s canal)
trabecular
meshwork)
Figure 1 GTS400 iStent inject® and G2-M-IS injector.
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Visit
Screening
Baseline
Day 1
Month 1
Month 3
Month 6
Month 9
Month 12

Two iStent inject®
n

Two medications
n

94
94
94
93
94
93
94
94

98
98
88
96
95
92
92
91
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Efficacy

Table 2 Demographics

Age (years)
Mean (SD)
 Range
Sex
Male/female
Race/ethnicity
White
Eye
OD/OS
Lens status
Phakic/pseudophakic

Two iStent inject®
(N=94)

Two medications
(N=98)

64.5 (10.3)
26–83

64.3 (9.8)
39–83

37 (39%)/57 (61%)

48 (49%)/50 (51%)

94 (100%)

98 (100%)

41 (44%)/53 (56%)

47 (48%)/51 (52%)

92 (98%)/2 (2%)

95 (97%)/3 (3%)

Abbreviations: OD, right eye; OS, left eye; SD, standard deviation.

was 64.5±10.3 years versus 64.3±9.8 years for the group receiving medical therapy. Of the 94 subjects in the iStent inject group,
61% were female and 39% were male versus 51% female and
49% male for the medical therapy group. All subjects in both
groups were Caucasian. The majority of eyes in both groups
were phakic (98% versus 97% for the iStent inject and medication groups, respectively). No subjects enrolled in the trial had
undergone prior selective laser trabeculoplasty. As an alternative
to the use of Xalacom (latanoprost/timolol), eight subjects were
administered with Duotrav® (travoprost/timolol; Alcon, Inc.,
Hünenberg, Switzerland), a medication similar to Xalacom in
mechanism of action. Four eyes in the iStent inject group were
taking medication at the month 12 examination.

At the month 12 visit, 94.7% of eyes (89/94) in the iStent
inject group reported an unmedicated IOP reduction $20%
versus baseline unmedicated IOP, and 91.8% of eyes (88/98)
in the medical therapy group reported an IOP reduction
$20% versus baseline unmedicated IOP (Figure 3). A 17.5%
between-group treatment difference in favor of the iStent
inject group was statistically significant (P=0.02) at the $50%
level of IOP reduction. An IOP #18 mmHg was reported in
92.6% of eyes (87/94) in the stent group and 89.8% of eyes
(88/98) in the medical therapy group (Figure 4).
At month 12, mean IOP in the iStent inject group was 13.0
(SD 2.3) mmHg versus 21.1 (SD 1.7) mmHg at screening
and 25.2 (SD 1.4) mmHg at baseline. A mean IOP decrease
from screening of 8.1 (SD 2.6) mmHg was reported in the
consistent cohort of subjects followed through month 12
(Table 3). For eyes in the medical therapy group, mean IOP
at month 12 was 13.2 (SD 2.0) mmHg versus 20.7 (SD 1.7)
mmHg at screening and 24.8 (SD 1.7) mmHg at baseline.
A mean IOP decrease from screening of 7.3 (SD 2.2) mmHg
was reported in the consistent cohort of subjects followed
through month 12.

Safety measurements
Vertical CD ratio data are provided in Table 4. The proportion of subjects with a CD ratio increase or decrease from
93.6

100

94.7
88.8

91.8

80.9
75.5
75
*P=0.02
53.2
iStent inject group

50

Medications group

35.7
25

0
M12 IOP reduction

≥50%

≥40%

≥30%

≥20%

iStent inject group
(%, 95% CI)
2-med group
(%, 95% CI)

53.2
(42.6, 63.6)
35.7
(26.3, 46.0)

80.9
(71.4, 88.2)
75.5
(65.8, 83.6)

93.6
(86.6, 97.6)
88.8
(80.8, 94.3)

94.7
(88.0, 98.3)
91.8
(84.5, 96.4)

Figure 3 Proportion of eyes with an M12 IOP reduction $50%, $40%, $30%, and $20%, respectively, for the iStent inject eyes without medication versus the two
medications group, with a nonresponder assumption for missing data. A between-group difference was significant (P=0.02) at the $50% level of IOP reduction.
Abbreviations: CI, confidence interval; IOP, intraocular pressure; M12, month 12.
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85.1

Adverse events and other
postoperative observations

92.6 89.8
81.6

75
iStent inject group

50

Medications group

25

0
M12 IOP

≤15 mmHg

≤18 mmHg

iStent inject group
(%, 95% Cl)

85.1
(76.3, 91.6)

92.6
(85.3, 97.0)

2-med group
(%, 95% Cl)

81.6
(72.5, 88.7)

89.8
(82.0, 95.0)

Figure 4 Proportion of eyes with an M12 IOP #15 mmHg and #18 mmHg,
respectively, for the iStent inject eyes without medication versus the two-medications
group, with a nonresponder assumption for missing data.
Abbreviations: CI, confidence interval; IOP, intraocular pressure; M12, month 12.

preoperative data at month 12 was similar within groups and
between groups, and suggests that the CD ratio did not change
over the 12-month timeframe. The CD ratio was maintained
through month 12 in most eyes. The proportion of eyes with
BCVA of 20/40 or better was 84% preoperatively versus 79%
at month 12 in the iStent inject group and 87% preoperatively
versus 84% at month 12 in the medication group. Five subjects
in the iStent inject group and nine subjects in the medication
group experienced a slight decrease in BCVA; however, this was
anticipated in this population which included eyes with progression of preexisting cataract and other ocular problems.

Ocular adverse events and other postoperative observations
are summarized in Table 5. One adverse event was reported
in the iStent inject group – one subject experienced IOP
decompensation with an elevated IOP (48 mmHg). The
subject was treated with medication and the IOP was lowered to 25 mmHg. One subject had one stent reported as not
visible, which was resolved after neodymium-doped yttrium
aluminum garnet laser treatment to remove an apparent
obstruction. One subject reported soreness/discomfort that
was resolved following treatment with nonsteroidal antiinflammatory medications. Two adverse events were reported
in two subjects in the medical therapy group – mild burning
of the eye (suspected intolerance to Xalacom) and suspected
allergy to medication.

Discussion
A series of studies to treat OAG using the Glaukos microbypass iStent technology as a sole procedure was undertaken by the MIGS Study Group. The study group was
comprised of surgeons from many countries. Unlike the
present multicenter study, these MIGS surgeons performed
the procedures at a single site on a homogeneous population
in Armenia. One study in the series, to assess the implantation of two iStent devices in subjects with mild-to-moderate

Table 3 Mean intraocular pressure and intraocular pressure change by visit – all eyes
IOP
Two iStent inject (N=94)
IOP over time
 N
Mean (SD)
IOP change from screening
 N
Mean (SD)
IOP change from baseline
 N
Mean (SD)
Two medications (N=98)
IOP over time
 N
Mean (SD)
IOP change from screening
 N
Mean (SD)
IOP change from baseline
 N
Mean (SD)

Screening

Baseline washout

Month 1

Month 3

Month 6

Month 9

Month 12

94
21.1 (1.7)

94
25.2 (1.4)

93
13.3 (4.1)

94
12.8 (3.2)

93
12.7 (3.2)

94
12.9 (2.9)

94
13.0 (2.3)

93
-7.7 (4.2)

94
-8.3 (3.3)

93
-8.5 (2.8)

94
-8.2 (3.0)

94
-8.1 (2.6)

93
-11.8 (4.2)

94
-12.4 (3.4)

93
-12.5 (3.2)

94
-12.3 (3.0)

94
-12.2 (2.5)

96
12.8 (2.6)

95
12.5 (2.8)

91
12.2 (2.2)

92
12.8 (2.9)

90
13.2 (2.0)

96
-7.9 (2.9)

95
-8.1 (2.6)

91
-8.3 (2.4)

92
-7.7 (2.8)

90
-7.3 (2.2)

96
-12.0 (2.9)

95
-12.3 (2.8)

91
-12.6 (2.4)

92
-11.9 (2.8)

90
-11.6 (2.2)

98
20.7 (1.7)

98
24.8 (1.7)

Abbreviations: IOP, intraocular pressure; SD, standard deviation.
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Table 4 Vertical cup-to-disc ratio change from baseline
Two iStents (N=94)
N
Better (decrease .0.2)
No change (change within ±0.2)
Worse (increase .0.2)
N (missing)
Two medications (N=98)
N
Better (decrease .0.2)
No change (change within ±0.2)
Worse (increase .0.2)
N (missing)

Month 1

Month 3

Month 6

Month 9

Month 12

92
2 (2%)
89 (97%)
0 (0%)
0

91
0 (0%)
89 (98%)
1 (1%)
2

92
0 (0%)
91 (99%)
1 (1%)
0

93
1 (1%)
89 (96%)
2 (2%)
0

93
0 (0%)
90 (97%)
1 (1%)
0

94
1 (1%)
92 (98%)
0 (0%)
1

93
0 (0%)
92 (99%)
0 (0%)
1

92
2 (2%)
90 (98%)
0 (0%)
0

91
0 (0%)
91 (100%)
0 (0%)
0

89
1 (1%)
88 (99%)
0 (0%)
1

OAG not controlled on one preoperative ocular hypotensive
medication, reported an average IOP of 13.6 mmHg at
1 year postoperatively without medication and without
significant postoperative effects, demonstrating that earlier
intervention of patients with mild-to-moderate OAG may
potentially be a preferable alternative to chronic use of
multiple medications.16 In another study, which assessed
two-stent implantation in 41 moderate-to-advanced OAG
phakic and pseudophakic patients not controlled on two
medications preoperatively, all eyes achieved month 12
IOP reduction $20% with reduction of one medication and
month 12 IOP #18 mmHg with reduction of one medication.
Mean IOP reduction .10 mmHg on one medication was
sustained through 18 months.17
The Second Line Study, described in this report, was
designed in recognition of the European Glaucoma Society
guidelines that specify addition of a second medication in
primary OAG prior to surgery.18 This pan-European, mul
ticenter study considered surgery with a new MIGS device
as an alternative to a second medication under a prospective, randomized study design of the iStent inject device
versus a fixed combination of prostaglandin/beta-blocker.
A significantly higher proportion of iStent inject eyes versus
Table 5 Ocular adverse events and other postoperative
observations

Eye burning
IOP decompensation
Medication allergy
One stent not visible
(treated with Nd:YAG laser)
Soreness/discomfort

iStent inject
group (N=94)

Medical therapy
group (N=98)

0 (0%)
1 (1%)
0 (0%)
1 (1%)

1 (1%)
0 (0%)
1 (1%)
0 (0%)

1 (1%)

0 (0%)

Abbreviations: IOP, intraocular pressure; Nd:YAG, neodymium-doped yttrium
aluminum garnet.
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medication eyes achieved month 12 IOP reduction $50%
versus baseline IOP. Mean IOP in the iStent inject group at
1 year was 13.0 mmHg versus 13.2 mmHg in the medication
group. Mean IOP decrease from baseline (12.2 mmHg in the
iStent inject group versus 11.6 in the medication group) was
reported. These data show that the use of iStent inject is at
least as effective as two medications, with the clinical benefit
of reducing medication burden and assuring continuous treatment with full compliance to implant therapy.
A high iStent implant safety profile was also noted in this
study, as measured by stable BCVA, CD ratio, and adverse
events. The low rate of reported adverse events is consistent
with work by Arriola-Villalobos on the first-generation stent,
in which one eye experienced visual acuity loss due to macular degeneration and one eye required topical medication for
increased IOP, in a series of 19 eyes with follow-up through a
mean of 54 months.7 Fea et al’s series of ten iStent subjects
and 14 control subjects followed for 56 months reported no
adverse events in the treatment group and macular drusen in
one subject in the control group.6
This study has several strengths, including that it is a
multicenter study conducted in a large number of countries,
which provides external validation of results. The use of
trabecular micro-bypass stents versus ocular hypotensive
medications to control IOP is an important development.
Newer drugs, such as actin cytoskeleton agents or rhoassociated protein kinase inhibitors, are targeted to alter the
compromised trabecular meshwork and improve outflow.19
However, patient compliance with chronic, long-term use of
topical medications and the associated side effects has been
demonstrably poor and is always suspect. Noncompliance
with medical therapy, leading to disease progression and
eventually to blindness, may be preventable by implantation
of this device.

Clinical Ophthalmology 2014:8
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There are several limitations in this work, including
that it was not a masked study due to the disparate forms
of therapy (surgery in one group, medication in the other
group). Because of the qualifying IOP requirement, lower
dispersion of IOP measurement data or regression to the
mean may have occurred. However, these limitations are
highly unlikely to have altered the findings that two iStent
inject devices provide comparable benefits to combination
medical therapy for OAG subjects.
Long-term follow-up studies are important in order to
evaluate efficacy and adverse effects past a 1-year timeframe. For example, long-term data from Craven et al,4 Fea
et al,6 and Arriola-Villalobos et al7 on the first-generation
iStent showed sustained IOP reduction and excellent safety
through ,56 months postoperatively. Because the first- and
second-generation trabecular micro-bypass devices are both
based on the trabecular bypass principle,2 similar favorable
long-term efficacy and safety of the iStent inject is expected.
Future studies that can assess the use of the iStent inject for
a timeframe .1 year are recommended to assess long-term
findings. A future summary of patient questionnaire findings from this study is also recommended as this report was
limited to safety and efficacy clinical data. Furthermore, this
study was limited to white patients only. As some patients,
such as black patients, may exhibit higher resistance to
glaucoma medical therapy, it is possible that trabecular
micro-bypass stents may be of even greater benefit in some
racial groups. It is recommended that future work expands
the demographic population so that the benefit of the iStent
inject can be further evaluated. In this study, stents were
placed in the nasal quadrant because this area features the
highest distribution of collector channels.20 The authors envision that future studies can examine optimum placement of
stents near the opening of major collector channels using
newer imaging technologies that can readily identify these
physiological structures.21 Finally, although subjects in the
medication group were instructed to follow the postoperative medication regimen (and were provided eye drops at no
cost to them), the authors relied on the subjects’ responses
that they complied with the protocol-specified medication
regimen as evidence that the subjects took their eye drops.
However, the substantial IOP reduction after treatment suggests strong compliance by the patients.

Conclusion
The favorable results of this third in a series of studies of the
MIGS Study Group confirms that micro-invasive surgery
using the iStent inject has the potential to be a valid alternative
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to medication for first-line therapy for mild-to-moderate OAG.
The data presented in this publication represent the status
of the patients 1 year after surgery; longer-term studies are
underway. This study confirms that the iStent inject is a safe
and effective implant procedure with a high benefit-to-risk
profile and may be a preferable alternative to chronic use of
multiple medications in subjects with OAG.
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